Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20704553 | 0.89 | MTNR1A (0.46) | TUBB1KMT2AMEN1LMNANR4A2 | |
| SCHEMBL20704864 | 0.82 | TUBB1 (0.46) | TUBB1KMT2AMEN1LMNA | |
| SCHEMBL20704906 | 0.82 | TUBB1 (0.46) | TUBB1ABCG2ADORA3ABCB1LMNA | |
| SCHEMBL20704965 | 0.81 | ALDH1A1 (0.48) | TUBB1KMT2AMEN1ABCG2KDM4E | |
| SCHEMBL1563089 | 0.80 | TUBB1 (0.67) | TUBB1 | |
| SCHEMBL20704950 | 0.75 | NPC1 (0.45) | TUBB1KMT2AMEN1ABCG2LMNA | |
| SCHEMBL20704865 | 0.72 | GABRA1 (0.51) | TUBB1KMT2AMEN1LMNAMTNR1A | |
| SCHEMBL20704636 | 0.72 | CFTR (0.55) | KMT2AMEN1ABCG2LMNA | |
| SCHEMBL20704872 | 0.72 | MTNR1A (0.50) | TUBB1KMT2AMEN1LMNAKDM4E | |
| SCHEMBL27942149 | 0.72 | TUBB1 (0.46) | TUBB1KMT2AMEN1ABCG2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230113225-A1 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | AXIAL THERAPEUTICS, INC. (US) | 2023-04-13 | — | — | US | disclosed |
| US-20230103887-A1 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | AXIAL THERAPEUTICS, INC. (US) | 2023-04-06 | — | — | US | disclosed |
| US-11505528-B2 | Inhibitors of microbially induced amyloid | AXIAL THERAPEUTICS, INC. (US) | 2022-11-22 | — | — | US | disclosed |
| US-11505528-B2 | Inhibitors of microbially induced amyloid | AXIAL THERAPEUTICS, INC. (US) | 2022-11-22 | — | — | US | disclosed |
| US-20220133634-A1 | SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME | AXIAL THERAPEUTICS, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| US-20210052503-A1 | SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME | AXIAL THERAPEUTICS, INC. (US) | 2021-02-25 | — | — | US | disclosed |
| WO-2020227437-A1 | SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME | AXIAL BIOTHERAPEUTICS, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| US-20200290970-A1 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | AXIAL BIOTHERAPEUTICS, INC. (US) | 2020-09-17 | — | — | US | disclosed |
| US-20200290970-A1 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | AXIAL BIOTHERAPEUTICS, INC. (US) | 2020-09-17 | — | — | US | disclosed |
| WO-2019028456-A1 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | AXIAL BIOTHERAPEUTICS, INC. (US) | 2019-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230103887-A1 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | SNCA, PARK7, PRNP | TUBB1 241/4885KMT2A 4786/4885MEN1 4376/4885 |
| US-11505528-B2 | Inhibitors of microbially induced amyloid | SNCA, PARK7, PRNP | TUBB1 241/4885KMT2A 4786/4885MEN1 4376/4885 |
| US-20230113225-A1 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | SNCA, PARK7, PRNP | TUBB1 305/4885KMT2A 4816/4885MEN1 4393/4885 |
| US-20210052503-A1 | SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME | APC, SNCA, PARK7 | TUBB1 1204/4885KMT2A 3735/4885MEN1 3511/4885 |
| US-20220133634-A1 | SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME | APC, SNCA, PARK7 | TUBB1 1204/4885KMT2A 3735/4885MEN1 3511/4885 |
| US-20200290970-A1 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | SNCA, PARK7, PRNP | TUBB1 241/4885KMT2A 4786/4885MEN1 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.